DHR

Danaher Corporation reported Q3 adjusted EPS of $2.11, beating estimates by 9.9%, with revenues of $6.55 billion in line with expectations. The company raised its 2026 adjusted EPS guidance to $8.57-$8.62 and expects 2.5% core revenue growth. Diagnostics segment sales jumped 17% driven by acquisitions, though respiratory testing revenues declined significantly from $500M to $350M year-over-year.

Danaher reported Q3 2026 earnings of $2.11 per share, beating consensus estimates of $1.92 and delivering a 9.90% earnings surprise. Revenue of $6.55 billion slightly exceeded expectations.

Despite the strong earnings beat, DHR shares have underperformed the S&P 500 by 14.4% year-to-date. The stock holds a Zacks Rank #2 (Buy) rating, though the Medical Services industry ranks in the bottom 34% of sectors.

Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy).